Skip to content

Released May 14, 2025, before the open

10-Q filed May 14, 2025, 44 days after period end · 0001628280-25-025312

Q1 2025 · 10-Q
Revenue$5.95M+17.9% vs Q1 2024+108.4% vs Q4 2024
Net Income-$18.83MN/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.30N/M vs Q1 2024no prior Q4 2024 on file
Operating Income-$22,913,000N/M
Operating Cash Flow-$23,968,000N/M
Free Cash Flowderived-$23,996,000N/M
Margins · derived
Operating margin-385.0%+173.3 pt vs Q1 2024
Net margin-316.4%+178.9 pt vs Q1 2024

What the release said

The release

Same quarter

MetricQ1 2025Q1 2024Q1 2023Q1 2022
Revenue$5.95M$5.05M$5.31M$3.92M
Net Income-$18.83M-$25.02M-$30.49M-$26.91M
EPS Diluted-$0.30-$0.59-$0.73-$0.65

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR